Vanguard Group’s Blueprint Medicines BPMC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-6,416,603
| Closed | -$822M | – | 4356 |
|
|
2025
Q2 | $822M | Sell |
6,416,603
-223,920
| -3% | -$23.3M | 0.01% | 767 |
|
|
2025
Q1 | $588M | Sell |
6,640,523
-134,361
| -2% | -$13.1M | 0.01% | 898 |
|
|
2024
Q4 | $591M | Buy |
6,774,884
+91,450
| +1% | +$8.38M | 0.01% | 940 |
|
|
2024
Q3 | $618M | Buy |
6,683,434
+144,968
| +2% | +$14.4M | 0.01% | 914 |
|
|
2024
Q2 | $705M | Buy |
6,538,466
+228,489
| +4% | +$22.9M | 0.01% | 795 |
|
|
2024
Q1 | $599M | Buy |
6,309,977
+195,007
| +3% | +$16.7M | 0.01% | 899 |
|
|
2023
Q4 | $564M | Buy |
6,114,970
+147,827
| +2% | +$9.58M | 0.01% | 901 |
|
|
2023
Q3 | $300M | Buy |
5,967,143
+37,716
| +0.6% | +$2.02M | 0.01% | 1208 |
|
|
2023
Q2 | $375M | Buy |
5,929,427
+50,483
| +0.9% | +$2.74M | 0.01% | 1100 |
|
|
2023
Q1 | $264M | Buy |
5,878,944
+104,488
| +2% | +$4.71M | 0.01% | 1298 |
|
|
2022
Q4 | $253M | Buy |
5,774,456
+113,353
| +2% | +$5.44M | 0.01% | 1305 |
|
|
2022
Q3 | $373M | Buy |
5,661,103
+44,292
| +0.8% | +$2.84M | 0.01% | 1007 |
|
|
2022
Q2 | $284M | Buy |
5,616,811
+91,751
| +2% | +$5.37M | 0.01% | 1205 |
|
|
2022
Q1 | $353M | Sell |
5,525,060
-8,711
| -0.2% | -$625K | 0.01% | 1191 |
|
|
2021
Q4 | $593M | Sell |
5,533,771
-49,361
| -0.9% | -$5.16M | 0.01% | 895 |
|
|
2021
Q3 | $574M | Buy |
5,583,132
+17,589
| +0.3% | +$1.64M | 0.01% | 900 |
|
|
2021
Q2 | $490M | Buy |
5,565,543
+51,714
| +0.9% | +$4.74M | 0.01% | 1002 |
|
|
2021
Q1 | $536M | Buy |
5,513,829
+327,317
| +6% | +$32.7M | 0.01% | 912 |
|
|
2020
Q4 | $582M | Buy |
5,186,512
+391,732
| +8% | +$41.3M | 0.02% | 800 |
|
|
2020
Q3 | $444M | Sell |
4,794,780
-134,430
| -3% | -$10.4M | 0.01% | 826 |
|
|
2020
Q2 | $384M | Buy |
4,929,210
+52,550
| +1% | +$3.55M | 0.01% | 884 |
|
|
2020
Q1 | $285M | Buy |
4,876,660
+508,676
| +12% | +$32.7M | 0.01% | 922 |
|
|
2019
Q4 | $350M | Buy |
4,367,984
+26,649
| +0.6% | +$2M | 0.01% | 1023 |
|
|
2019
Q3 | $319M | Buy |
4,341,335
+59,973
| +1% | +$5.18M | 0.01% | 1038 |
|
|
2019
Q2 | $404M | Buy |
4,281,362
+321,857
| +8% | +$26.6M | 0.02% | 903 |
|
|
2019
Q1 | $317M | Buy |
3,959,505
+141,543
| +4% | +$10.5M | 0.01% | 1044 |
|
|
2018
Q4 | $206M | Buy |
3,817,962
+82,572
| +2% | +$5.02M | 0.01% | 1229 |
|
|
2018
Q3 | $292M | Buy |
3,735,390
+111,972
| +3% | +$7.78M | 0.01% | 1136 |
|
|
2018
Q2 | $230M | Buy |
3,623,418
+241,363
| +7% | +$19.2M | 0.01% | 1260 |
|
|
2018
Q1 | $310M | Buy |
3,382,055
+65,127
| +2% | +$5.61M | 0.01% | 1014 |
|
|
2017
Q4 | $250M | Buy |
3,316,928
+1,382,699
| +71% | +$97.3M | 0.01% | 1149 |
|
|
2017
Q3 | $135M | Buy |
1,934,229
+518,266
| +37% | +$27.7M | 0.01% | 1526 |
|
|
2017
Q2 | $71.7M | Buy |
1,415,963
+195,517
| +16% | +$8.3M | ﹤0.01% | 1840 |
|
|
2017
Q1 | $48.8M | Buy |
1,220,446
+313,181
| +35% | +$11.2M | ﹤0.01% | 2021 |
|
|
2016
Q4 | $25.4M | Buy |
907,265
+194,790
| +27% | +$5.87M | ﹤0.01% | 2314 |
|
|
2016
Q3 | $21.2M | Buy |
712,475
+145,480
| +26% | +$3.61M | ﹤0.01% | 2338 |
|
|
2016
Q2 | $11.5M | Buy |
566,995
+39,253
| +7% | +$713K | ﹤0.01% | 2592 |
|
|
2016
Q1 | $9.53M | Buy |
527,742
+23,286
| +5% | +$404K | ﹤0.01% | 2638 |
|
|
2015
Q4 | $13.3M | Buy |
504,456
+288,880
| +134% | +$6.5M | ﹤0.01% | 2483 |
|
|
2015
Q3 | $4.6M | Buy |
215,576
+30,705
| +17% | +$849K | ﹤0.01% | 3007 |
|
|
2015
Q2 | $4.9M | Buy |
+184,871
| New | +$5.28M | ﹤0.01% | 3030 |
|
Other funds holding BPMC
IA
HNB
Vanguard Group's BPMC Position: Q3 2025 in Review
Vanguard Group sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 6,416,603 shares — an estimated $822M sold.
Vanguard Group first reported a position in BPMC in Q2 2015 and held it in 41 quarters. The position peaked at $822M in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.
- Vanguard Group reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
- Vanguard Group sold 6,416,603 Blueprint Medicines shares in Q3 2025, an estimated $822M.
- Vanguard Group first reported a position in Blueprint Medicines in Q2 2015 and held it in 41 quarters.
- Vanguard Group's Blueprint Medicines position peaked at $822M in Q2 2025.
- 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.
Based on Vanguard Group's 13F filing for Q3 2025, filed 7 Nov 2025.